

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Shigeo OHTA et al. : Attn: BOX PCT

Serial No. NEW : Docket No. 2002\_0256A

Filed February 19, 2002

A GENETICALLY ENGINEERED cDNA OF  
RAT bc1-x GENE AND AN IMPROVED PROTEIN  
[Corresponding to PCT/JP00/05502  
Filed August 17, 2000]

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in international application no. PCT/JP00/05502.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action

and thus no certification and/or fee is required.

- 1b.  This Information Disclosure Statement is submitted  
after the events of above paragraph 1a and prior to the mailing date of a final Office Action  
or a Notice of Allowance or an action which otherwise closes prosecution in the  
application, and thus:  
  
(1)  the certification of paragraph 2 below is provided, **or**  
  
(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c.  This Information Disclosure Statement is submitted:  
after the mailing date of a final Office Action or Notice of Allowance or action which  
otherwise closes prosecution in the application, and prior to payment of the issue fee, and  
thus:  
  
**the certification of paragraph 2 below is provided, and**  
  
**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**
2. It is hereby certified  
  
a.  that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or  
  
b.  that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
3.  Consideration of the following list of additional information (including any copending or  
pending U.S. applications and/or foreign applications) is requested

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a full or partial English language translation submitted herewith,
  - a foreign patent office search report (in the English language) submitted herewith,
  - the concise explanation contained in the specification of the present application at page,
  - the concise explanation set forth in the attached English language abstract,
  - the concise explanation set forth below or on a separate sheet attached to the reference:
5.  A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Shigeo OHTA et al.

By Warren Cheek Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
February 19, 2002

10/049822

19 FEB 2002

JG13 Rec'd PTO 7:00

Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: February 19, 2002

ATTY DOCKET NO.  
2002\_0256ASERIAL NO.  
NEWAPPLICANT  
Shigeo OHTA et al.FILING DATE  
February 19, 2002

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AE						
	AF						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AG	M. Aritomi et al., "Crystal Structure of Rat Bc1-x <sub>1</sub> ", J. Biol. Chem., Vol. 272, No. 44, pp. 27886-27892, 1997.
	AH	W. Fang et al., "Cloning and Molecular Characterization of Mouse bc1-x in B and T Lymphocytes", J. Immunol., Vol. 153, No. 10, pp. 4388-4394, 1994.
	AI	D.A.M. Grillot et al., "Genomic Organization, Promoter Region Analysis, and Chromosome Localization of the Mouse bc1-x Gene", J. Immunol., Vol. 158, No. 10, pp. 4750-4757, 1994.
	AJ	N. Shirakawa et al., "An Additional Form of Rat Bc1-x, Bc1-x β, Generated by an Unspliced RNA, Promotes Apoptosis in Promyeloid Cells", J. Biol. Chem., Vol. 271, No. 22, pp. 13258-13265, 1996.
	AK	M. Gonzalez-Garcia et al., "bc1-x is the Major bc1-x mRNA form Expressed During Murine Development and its Product Localizes to Mitochondria", Vol. 120, Development, No. 10, pp. 3033-3042, 1994.
	AL	J. L. Tilly et al., "Expression of Members of the Bc1-2 Gene Family in the Immature Rat Ovary: Equine Chorionic Gonatropin-Mediated Inhibition of Granulosa Cell Apoptosis is Associated with Decreased Bax and Constitutive Bc1-2 and Bc1-x <sub>king</sub> Messenger Ribonucleic Acid Levels", Endocrinology, Vol. 136, No. 1, pp. 232-241, 1995.

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.